Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial

Wiedemann, Peter; Hilgers, Ralf-Dieter; Bauer, Peter; Heimann, Klaus

doi:10.1016/s0002-9394(98)00115-9

Cited by 172 publications

(123 citation statements)

References 15 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…These data suggest that a prophylactic, post-surgical intravitreal injection of a cocktail of antibodies targeted against CTGF, HGF, and PDGF may help reduce the recurrence of PVR. A treatment strategy that targets these growth factors, or their receptors, may be more beneficial in inhibiting PVR development, than nonspecific antiproliferative agents, such as heparin, 36 daunorubicin, 37 5-fluorouracil (5-FU), 38 colchicine, 39 taxol, 40 radiation 41 or a ribozyme technology targeted to proliferating cell nuclear antigen (PCNA). 42 …”

Section: Colocalization Of Pdgf With Rpe and Glial In Pvr Membranementioning

confidence: 99%

Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy

Cui

Chiu

Maberley

et al. 2006

Eye

View full text Add to dashboard Cite

show abstract

Section: Colocalization Of Pdgf With Rpe and Glial In Pvr Membranementioning

confidence: 99%

Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy

Cui

Chiu

Maberley

et al. 2006

Eye

View full text Add to dashboard Cite

show abstract

“…The first reported randomised controlled trials on the use of adjunctive agents in the management of PVR was the European Daunorubicin trial co-ordinated by Wiedemann and colleagues. 38 This was a multicentre randomised controlled trial recruiting patients with established PVR. A 10-min infusion of Daunorubicin at the time of vitrectomy surgery was used in the treatment group.…”

Section: Adjunctive Treatmentmentioning

confidence: 99%

Proliferative vitreoretinopathy—developments in adjunctive treatment and retinal pathology

Charteris

Sethi

Lewis

et al. 2002

Eye

174

102

View full text Add to dashboard Cite

“…DNR has been applied topically in strabismus surgery, pterygium surgery, and experimental and clinical vitreoretinopathy surgery. It has been shown that reproliferation decreases (1,37,38). In glaucoma, its anti-fibroblastic effect has been shown both experimentally and clinically.…”

Section: █ Discussionmentioning

confidence: 99%

“…At the same time, it can lead to pulmonary fibrosis and kidney damage. No serious side effects after topical application of MMC and DNR have been observed (1,2,5,6,30,35,37,38). MMC and DNR were used topically in our study for anti-adhesion effects.…”

mentioning

confidence: 85%

“…findings that it inhibits the activation of fibroblast proliferation in ophthalmology (1,5,37,38). Mitomycin C (MMC) is already in use primarily for anti-tumor activity of adenocarcinomas and carcinomas of the genitourinary tract, but also as a broadly used topical agent in ophthalmology for prevention of postoperative fibrosis, especially in strabismus surgery, refractive corneal surgery and trabeculectomy in glaucoma surgery (4,26,32,36,42).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prevention of epidural fibrosis in rats by local administration of mitomycin c or daunorubicin

Vural¹,

Yılmaz²,

İlbay³

et al. 2013

Turkish Neurosurgery

View full text Add to dashboard Cite

ABSTRACTsurgical techniques have been developed to reduce and prevent epineural scar formation (microsurgical techniques, endoscopic techniques, nerve transposition, dermofascial fat grafts, and muscle flap) (34). Daunorubicin or daunomycin (DNR) is a chemotherapeutic agent that is a member of the anthracycline family. It is used for some types of cancer treatment. Mostly, it is used for the treatment of specific types of leukemia (acute myeloid leukemia and acute lymphocytic leukemia). Daunorubicin usage is recommended locally after pterygium surgery, glaucoma surgery and strabismus surgery due to █ INTRODUCTIONThe main reason for the failure of peripheral nerve surgery is post-operative adhesion after surgery. Intraoperative nerve injury, bleeding or a simple manipulation of the nerve can result formation of scar tissue via thickening of the epineurium. Nerve compression that is caused by postoperative scarring may result in functional impairment and pain. Strong and prolonged adhesion of nerves to adjacent structures can give rise to ischemia and further nerve injury (22,27,33,39). Many AIM: Epineural adhesion after peripheral nerve surgery is common. The purpose of this study was to evaluate the macroscopic and histopathologic effects of topical mitomycin C and daunorubicin on epineural scar formation. MATERIAl and METhODS:In this study, we used 15 rats (30 nerves). Two test groups and one control group were created. Sciatic nerve exposure was created bilaterally in each group (30 nerve examinations in total). In experimental group 1, cotton pads that had absorbed mitomycin C (0.5 mg/ml) were placed onto the nerves for 5 minutes while in experimental group 2, cotton pads that had absorbed daunorubicin (0.2 mg/ml) were placed onto the nerves for 5 minutes and cotton pads that had absorbed saline were applied to the control group. Eight weeks after the first surgery, surgical dissection was performed for the evaluation of neurolysis sites. Epineural adhesions were classified utilizing a numerical grading layout. RESUlTS:We did not find any adverse effect with topically applied mitomycin C and daunorubicin. Within the 3 groups, no significant difference was seen in skin and fascia-muscle cavity closure (p>0.05). Macroscopically, mitomycin C and daunorubicin decreased the adhesion of sciatic nerve to adjacent structures. There was intensive epineural scar formation in the control group. Scar tissue thickness and fibroblast/fibrocyte cell number were less in the two test groups compared with the control group (p<0.001). There was no statistical difference between the two test groups.CONClUSION: Epineural scar formation after peripheral nerve surgery may be reduced by using topical application of mitomycin C and daunorubicin.

show abstract

Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial

Cited by 172 publications

References 15 publications

Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy

Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy

Proliferative vitreoretinopathy—developments in adjunctive treatment and retinal pathology

Prevention of epidural fibrosis in rats by local administration of mitomycin c or daunorubicin

Contact Info

Product

Resources

About